24 May 2013 - United States-based Acorda Therapeutics has received an additional US patent for ampyra covering a range of dosage strengths, it was reported yesterday.

The product is indicated for treatment to improve walking in patients with multiple sclerosis.

The patent includes methods of improving lower extremity function and walking and increasing walking speed in multiple sclerosis patients, by administering less than 15mg of sustained release 4-aminopyridine (dalfampridine) twice a day.